Grail (NASDAQ:GRAL) Coverage Initiated by Analysts at Morgan Stanley

Morgan Stanley assumed coverage on shares of Grail (NASDAQ:GRAL) in a research report released on Wednesday morning, MarketBeat.com reports. The firm issued an equal weight rating and a $16.00 price objective on the stock.

Other research analysts have also issued research reports about the company. Guggenheim started coverage on Grail in a research report on Thursday, October 17th. They set a “neutral” rating for the company. Wolfe Research initiated coverage on Grail in a report on Friday, November 15th. They issued a “peer perform” rating for the company.

Grail Price Performance

GRAL opened at $17.45 on Wednesday. The company has a 50 day moving average price of $14.22. Grail has a 52 week low of $12.33 and a 52 week high of $23.36.

Insider Transactions at Grail

In related news, CFO Aaron Freidin sold 30,452 shares of Grail stock in a transaction on Monday, November 18th. The stock was sold at an average price of $14.02, for a total transaction of $426,937.04. Following the transaction, the chief financial officer now directly owns 268,277 shares in the company, valued at approximately $3,761,243.54. The trade was a 10.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Ragusa sold 123,454 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total value of $1,730,825.08. Following the completion of the transaction, the chief executive officer now owns 612,661 shares in the company, valued at $8,589,507.22. The trade was a 16.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have bought a total of 58,829 shares of company stock worth $757,298 in the last ninety days.

About Grail

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.